Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
Authors
Keywords
-
Journal
International Journal of Rheumatic Diseases
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-10-19
DOI
10.1111/1756-185x.13401
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation
- (2017) Le-Feng Chen et al. International Journal of Rheumatic Diseases
- Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan
- (2016) Wataru Fukuda et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection
- (2016) Melissa Padovan et al. ARTHRITIS CARE & RESEARCH
- Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report
- (2016) Rossella Talotta et al. BMC Pharmacology & Toxicology
- Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection
- (2015) Michele Barone et al. HEPATOLOGY
- Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare
- (2015) Huifeng Yun et al. Arthritis & Rheumatology
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
- (2014) Sofia Ramiro et al. ANNALS OF THE RHEUMATIC DISEASES
- JSH Guidelines for the Management of Hepatitis B Virus Infection
- (2014) HEPATOLOGY RESEARCH
- Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
- (2014) Jun Nakamura et al. International Journal of Rheumatic Diseases
- Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
- (2014) Wai-Kay Seto et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis
- (2013) Hua-Jie Dong et al. JOURNAL OF CLINICAL VIROLOGY
- A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy
- (2013) Masayoshi Harigai et al. Modern Rheumatology
- Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection
- (2013) A. Fanouriakis et al. RHEUMATOLOGY
- Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
- (2012) Makoto Oketani et al. HEPATOLOGY RESEARCH
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- (2012) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis
- (2011) Yu Xuan Koo et al. ANNALS OF HEMATOLOGY
- Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy
- (2011) J.-L. Lan et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
- (2011) Simone Lanini et al. BMC Medicine
- Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts
- (2011) Akihiro Tamori et al. JOURNAL OF GASTROENTEROLOGY
- Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept
- (2011) Georgios Germanidis et al. JOURNAL OF HEPATOLOGY
- Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases
- (2011) MASARU KATO et al. JOURNAL OF RHEUMATOLOGY
- Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety
- (2011) Y. KOMANO et al. JOURNAL OF RHEUMATOLOGY
- Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy
- (2011) Roberto Pérez-Alvarez et al. MEDICINE
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) D. Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases
- (2010) R. Caporali et al. ARTHRITIS CARE & RESEARCH
- Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients
- (2009) Caroline Charpin et al. ARTHRITIS RESEARCH & THERAPY
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
- (2008) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation